Portfolio pick:
Granules India NSE -1.17 % has announced that Granules Pharmaceutical, its wholly-owned foreign subsidiary located at Virginia, USA, has cleared a pre-approved inspection for three applications filed in that facility. This is good news for the company. As it plays on the defensive side of the market, it is a good stock to have in your portfolio. On technical grounds, Granules India, after a long consolidation on weekly charts, has given a horizontal breakup. Volumes have also marginally increased. Both RSI and MACD are in favour and above 400. It will make a good up move. The target price level for Granules India will be Rs 450 and one should keep a stop loss at Rs 350.
Trade with Raj
#granules #granulesindia #pharmaceuticalindustry #tradewithraj #brainmassinvestors #buyandhold #portfoliostock #longterminvesting
Granules India NSE -1.17 % has announced that Granules Pharmaceutical, its wholly-owned foreign subsidiary located at Virginia, USA, has cleared a pre-approved inspection for three applications filed in that facility. This is good news for the company. As it plays on the defensive side of the market, it is a good stock to have in your portfolio. On technical grounds, Granules India, after a long consolidation on weekly charts, has given a horizontal breakup. Volumes have also marginally increased. Both RSI and MACD are in favour and above 400. It will make a good up move. The target price level for Granules India will be Rs 450 and one should keep a stop loss at Rs 350.
Trade with Raj
#granules #granulesindia #pharmaceuticalindustry #tradewithraj #brainmassinvestors #buyandhold #portfoliostock #longterminvesting